Literature DB >> 23325477

MicroRNAs in myocardial infarction.

Jan Fiedler1, Thomas Thum.   

Abstract

The complexity of posttranscriptional regulation by noncoding microRNAs (miRNAs, miRs) is still not completely understood. A large fraction of the genome is under the control of miRs via (partial) complementary base pairing within the corresponding mRNA region. Myocardial infarction is characterized by strongly altered gene expression, deregulation of underlying signaling pathways, and crucial participation of several miRs in this context. Mechanistically, miR induction or repression after myocardial infarction triggers downstream events in a cell-type-specific manner, and interference with endogenous miR expression might regulate overall cardiac function. In this brief review, we (1) summarize the current knowledge about the importance of several miRs after myocardial infarction, (2) report about novel miR-based therapeutic approaches to counteract maladaptive remodeling upon cardiac ischemia, and (3) discuss briefly the use of miRs as biomarkers for cardiac ischemia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23325477     DOI: 10.1161/ATVBAHA.112.300137

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  48 in total

Review 1.  MicroRNA control of high-density lipoprotein metabolism and function.

Authors:  Katey J Rayner; Kathryn J Moore
Journal:  Circ Res       Date:  2014-01-03       Impact factor: 17.367

2.  A cardiac myocyte-restricted Lin28/let-7 regulatory axis promotes hypoxia-mediated apoptosis by inducing the AKT signaling suppressor PIK3IP1.

Authors:  Shaurya Joshi; Jianqin Wei; Nanette H Bishopric
Journal:  Biochim Biophys Acta       Date:  2015-12-02

3.  My heart will go on-beneficial effects of anti-MiR-30 after myocardial infarction.

Authors:  Yuhuang Li; Lars Maegdefessel
Journal:  Ann Transl Med       Date:  2016-04

Review 4.  Circulating miR-499 as a potential biomarker for acute myocardial infarction.

Authors:  Yunyi Xin; Chengjian Yang; Zhijun Han
Journal:  Ann Transl Med       Date:  2016-04

Review 5.  Exosome and its roles in cardiovascular diseases.

Authors:  Wang Zhao; Xi-Long Zheng; Shui-Ping Zhao
Journal:  Heart Fail Rev       Date:  2015-05       Impact factor: 4.214

Review 6.  The emerging roles of long noncoding RNAs in common cardiovascular diseases.

Authors:  Xiaoying Jiang; Qilan Ning
Journal:  Hypertens Res       Date:  2015-03-12       Impact factor: 3.872

Review 7.  HypoxamiR regulation and function in ischemic cardiovascular diseases.

Authors:  Simona Greco; Carlo Gaetano; Fabio Martelli
Journal:  Antioxid Redox Signal       Date:  2013-11-12       Impact factor: 8.401

8.  Reactivation of the Nkx2.5 cardiac enhancer after myocardial infarction does not presage myogenesis.

Authors:  Marcus-André Deutsch; Stefanie A Doppler; Xinghai Li; Harald Lahm; Gianluca Santamaria; Giovanni Cuda; Stefan Eichhorn; Thomas Ratschiller; Elda Dzilic; Martina Dreßen; Annekathrin Eckart; Konstantin Stark; Steffen Massberg; Anna Bartels; Christoph Rischpler; Ralf Gilsbach; Lutz Hein; Bernd K Fleischmann; Sean M Wu; Rüdiger Lange; Markus Krane
Journal:  Cardiovasc Res       Date:  2018-07-01       Impact factor: 10.787

Review 9.  Cardiovascular consequences of metabolic syndrome.

Authors:  Johnathan D Tune; Adam G Goodwill; Daniel J Sassoon; Kieren J Mather
Journal:  Transl Res       Date:  2017-01-09       Impact factor: 7.012

10.  Differential expression of vascular smooth muscle-modulating microRNAs in human peripheral blood mononuclear cells: novel targets in essential hypertension.

Authors:  J E Kontaraki; M E Marketou; E A Zacharis; F I Parthenakis; P E Vardas
Journal:  J Hum Hypertens       Date:  2013-11-28       Impact factor: 3.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.